Subtopic Deep Dive
Mangiferin Neuroprotection
Research Guide
What is Mangiferin Neuroprotection?
Mangiferin neuroprotection refers to the neuroprotective effects of mangiferin, a xanthone from mango, against neurodegeneration, ischemia, and neuroinflammation through antioxidant, anti-apoptotic, and anti-inflammatory mechanisms.
Research demonstrates mangiferin protects neurons in models of Alzheimer's, Parkinson's, and spinal cord injury by reducing oxidative stress and modulating Bcl-2/Bax ratios (Alberdi et al., 2018; Kavitha et al., 2013). Key studies include 94-citation work on amyloid beta protection and 88-citation MPTP Parkinson's model. Over 10 papers from provided lists address these mechanisms, with 330-citation review on mangiferin bioactivity.
Why It Matters
Mangiferin reduces amyloid beta-induced mitochondrial dysfunction and neurocytotoxicity, offering potential for Alzheimer's therapy (Alberdi et al., 2018, 94 citations). In Parkinson's models, it attenuates dopaminergic neurodegeneration and improves motor function via redox balance and Bcl-2/Bax regulation (Kavitha et al., 2013, 88 citations). Spinal cord injury studies show mangiferin limits neurological pain by regulating oxidative stress and inflammation (Luo et al., 2015, 58 citations), positioning it as a candidate for stroke and neurodegenerative disease treatments.
Key Research Challenges
Blood-brain barrier penetration
Mangiferin's ability to cross the blood-brain barrier remains underexplored in vivo, limiting translation to human neurodegeneration therapies. Studies focus on peripheral effects but lack direct brain pharmacokinetics (Feng et al., 2019). This gap hinders clinical advancement.
Dose-response optimization
Optimal neuroprotective dosing varies across models like MPTP Parkinson's and amyloid beta, with inconsistent bioavailability reported. Kavitha et al. (2013) used specific regimens but broader standardization is needed. Human-equivalent doses require further pharmacokinetic modeling.
Long-term efficacy validation
Most evidence comes from acute rodent models, lacking chronic human-relevant trials for Alzheimer's or stroke. Alberdi et al. (2018) showed short-term protection, but sustained neuroprotection against progressive decline is unproven. Clinical translation faces this evidentiary shortfall.
Essential Papers
Mangiferin: a natural miracle bioactive compound against lifestyle related disorders
Muhammad Imran, Muhammad Sajid Arshad, Masood Sadiq Butt et al. · 2017 · Lipids in Health and Disease · 330 citations
Therapeutic potential of naringin in neurological disorders
Salman Ahmed, Haroon Khan, Michael Aschner et al. · 2019 · Food and Chemical Toxicology · 117 citations
Antioxidant therapy: myth or reality?
Alberto J. Núñez‐Sellés · 2005 · Journal of the Brazilian Chemical Society · 109 citations
New terms such as oxidative stress, antioxidant products or pro-oxidant risks are becoming familiar and an increasing number of international scientific conferences and the publication of thousands...
Mangiferin and Morin Attenuate Oxidative Stress, Mitochondrial Dysfunction, and Neurocytotoxicity, Induced by Amyloid Beta Oligomers
Elena Alberdi, Marı́a Victoria Sánchez-Gómez, Asier Ruiz et al. · 2018 · Oxidative Medicine and Cellular Longevity · 94 citations
Amyloid beta‐ (A β ‐) mediated ROS overproduction disrupts intraneuronal redox balance and exacerbates mitochondrial dysfunction which leads to neuronal injury. Polyphenols have been investigated a...
Mangiferin attenuates MPTP induced dopaminergic neurodegeneration and improves motor impairment, redox balance and Bcl-2/Bax expression in experimental Parkinson’s disease mice
Mani Kavitha, Jagatheesan Nataraj, Musthafa Mohamed Essa et al. · 2013 · Chemico-Biological Interactions · 88 citations
Mangiferin: A multipotent natural product preventing neurodegeneration in Alzheimer’s and Parkinson’s disease models
Sitong Feng, Zhen‐Zhen Wang, Yu‐He Yuan et al. · 2019 · Pharmacological Research · 86 citations
Mangiferin Ameliorates Cisplatin Induced Acute Kidney Injury by Upregulating Nrf-2 via the Activation of PI3K and Exhibits Synergistic Anticancer Activity With Cisplatin
Pritam Sadhukhan, Sukanya Saha, Sayanta Dutta et al. · 2018 · Frontiers in Pharmacology · 75 citations
Occurrence of oxidative stress is the principal cause of acute kidney injury induced by cisplatin. Mangiferin, a naturally occurring antioxidant molecule, is found to ameliorate several oxidative s...
Reading Guide
Foundational Papers
Start with Núñez-Sellés (2005, 109 citations) for antioxidant therapy context, then Kavitha et al. (2013, 88 citations) for MPTP Parkinson's mechanisms establishing Bcl-2/Bax modulation baselines.
Recent Advances
Study Alberdi et al. (2018, 94 citations) for amyloid beta mitochondrial protection and Feng et al. (2019, 86 citations) for multipotent effects in Alzheimer's/Parkinson's models.
Core Methods
Core techniques are rodent neurodegeneration models (MPTP, amyloid beta oligomers), redox assays, Bcl-2/Bax Western blots, and behavioral motor tests (Kavitha et al., 2013; Alberdi et al., 2018).
How PapersFlow Helps You Research Mangiferin Neuroprotection
Discover & Search
Research Agent uses searchPapers and exaSearch to find mangiferin neuroprotection literature, revealing Alberdi et al. (2018) as a 94-citation hub on amyloid beta protection. citationGraph maps connections from Kavitha et al. (2013) MPTP study to 88 related papers. findSimilarPapers expands from Feng et al. (2019) to similar xanthone neuroprotection works.
Analyze & Verify
Analysis Agent applies readPaperContent to extract mechanisms from Alberdi et al. (2018), then verifyResponse with CoVe checks claims against 10+ papers for consistency. runPythonAnalysis processes redox data from Kavitha et al. (2013) for Bcl-2/Bax ratio stats, with GRADE grading evidence as moderate due to preclinical focus.
Synthesize & Write
Synthesis Agent detects gaps like blood-brain barrier data via gap detection on Luo et al. (2015) and Feng et al. (2019). Writing Agent uses latexEditText and latexSyncCitations to draft reviews citing 330-citation Imran et al. (2017), with latexCompile for publication-ready output and exportMermaid for Bcl-2/Bax pathway diagrams.
Use Cases
"Extract and plot Bcl-2/Bax ratios from mangiferin Parkinson's studies"
Research Agent → searchPapers('mangiferin MPTP Bcl-2 Bax') → Analysis Agent → readPaperContent(Kavitha 2013) → runPythonAnalysis(pandas plot ratios) → matplotlib dose-response graph.
"Draft LaTeX review on mangiferin Alzheimer's neuroprotection"
Synthesis Agent → gap detection(Alberdi 2018, Feng 2019) → Writing Agent → latexEditText(intro mechanisms) → latexSyncCitations(10 papers) → latexCompile(PDF review with figures).
"Find code for mangiferin redox simulations in neuro models"
Research Agent → paperExtractUrls(Kavitha 2013) → paperFindGithubRepo(redox models) → githubRepoInspect → Code Discovery workflow outputs simulation scripts for MPTP neuroprotection.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ mangiferin papers, chaining searchPapers → citationGraph → GRADE grading for neuroprotective strength in Alzheimer's models. DeepScan applies 7-step analysis to Alberdi et al. (2018), verifying amyloid beta claims with CoVe checkpoints. Theorizer generates hypotheses on mangiferin-PI3K-Nrf2 pathways from Sadhukhan et al. (2018) for stroke neuroprotection.
Frequently Asked Questions
What is mangiferin neuroprotection?
Mangiferin neuroprotection is the protective action of mangiferin against neuronal damage from oxidative stress, apoptosis, and inflammation in models of Alzheimer's, Parkinson's, and spinal injury (Alberdi et al., 2018; Kavitha et al., 2013).
What are key methods in mangiferin neuroprotection studies?
Methods include MPTP mouse models for Parkinson's (Kavitha et al., 2013), amyloid beta oligomer assays for Alzheimer's (Alberdi et al., 2018), and contusive spinal cord injury in rats assessing Bcl-2/Bax and inflammation (Luo et al., 2015).
What are the highest-cited papers?
Top papers are Alberdi et al. (2018, 94 citations) on amyloid beta protection, Kavitha et al. (2013, 88 citations) on MPTP Parkinson's, and Imran et al. (2017, 330 citations) reviewing mangiferin bioactivity against disorders.
What open problems exist?
Challenges include blood-brain barrier penetration, long-term efficacy in chronic models, and human dosing translation, as preclinical rodent data dominates without clinical trials (Feng et al., 2019).
Research Mangiferin and Mango Extracts with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Mangiferin Neuroprotection with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Mangiferin and Mango Extracts Research Guide